Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | F11 | P03951 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19263962 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL4304071 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL14477067 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL9850189 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL18256380 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL16756962 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL4300188 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL4300564 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL812510 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL12595098 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD (SG) | 2025-08-21 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| EP-4507700-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2025-02-19 | — | — | EP | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201095-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-10-19 | — | — | WO | disclosed |
| US-7291726-B2 | Process for the preparation of 2′-halo-β-L-arabinofuranosyl nucleosides | BUKWANG PHARMACEUTICALS IND CO., LTD. (KR) | 2007-11-06 | — | — | US | disclosed |
| US-20050187384-A1 | Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides | TRIANGLE PHARMACEUTICALS | 2005-08-25 | — | — | US | disclosed |
| EP-1373288-B1 | PROCESS FOR THE PREPARATION OF 2'-HALO-BETA-L-ARABINOFURANOSYL NUCLEOSIDES | GILEAD SCIENCES INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6870048-B2 | Process for the preparation of 2'-halo-β-L-arabinofuranosyl nucleosides | TRIANGLE PHARMACEUTICALS (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1373288-A1 | PROCESS FOR THE PREPARATION OF 2'-HALO-BETA-L-ARABINOFURANOSYL NUCLEOSIDES | Triangle Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030060622-A1 | Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides | BUKWANG PHARMACEUTICAL IND CO., LTD. (KR) | 2003-03-27 | — | — | US | disclosed |
| WO-2002079213-A1 | PROCESS FOR THE PREPARATION OF 2'-HALO-$G(B)-L-ARABINOFURANOSYL NUCLEOSIDES | TRIANGLE PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
| US-6331287-B1 | NONCATABOLIZING IMAGING AGENT FOR POSITRON EMISSION TOMOGRAPHY; | UNIVERSITY ADVANCED BIO-IMAGING ASSOCIATES | 2001-12-18 | — | — | US | disclosed |
| US-5994321-A | Antiviral guanine analogs | ARONEX PHARMACEUTICALS, INC. (US) | 1999-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | PTPN1 1780/4885USP2 3365/4885POLB 127/4885 |
| US-20050187384-A1 | Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides | FUCA2, FUCA1, GALE | PTPN1 4803/4885USP2 3734/4885POLB 511/4885 |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | ADAR, RNGTT, NSUN2 | PTPN1 2325/4885USP2 3520/4885POLB 79/4885 |
| US-20030060622-A1 | Process for the preparation of 2'-halo-beta-L-arabinofuranosyl nucleosides | FUCA2, FUCA1, GALE | PTPN1 4817/4885USP2 3696/4885POLB 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.